Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 17/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 14/20 | 1.00 |
| ▸ | GLA | P06280 | 13/20 | 1.00 |
| ▸ | GAA | P10253 | 12/20 | 1.00 |
| ▸ | HPGD | P15428 | 11/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | ATM | Q13315 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CRHBP | P24387 | 1/20 | 0.55 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17887448 | 0.84 | KDM4E (0.72) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL18496673 | 0.84 | KDM4E (0.72) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL4888217 | 0.79 | ALDH1A1 (0.66) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL1694465 | 0.76 | KDM4E (0.62) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL30785581 | 0.76 | KDM4E (0.60) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL2267098 | 0.73 | KDM4E (1.00) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL2593981 | 0.73 | KDM4E (0.60) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL2587156 | 0.73 | KDM4E (0.57) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL28600246 | 0.72 | ALDH1A1 (0.89) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL2089578 | 0.72 | ALDH1A1 (0.80) | KDM4EALDH1A1GLAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118852123-A | Novel heterocyclic compounds as Pol theta inhibitors for the treatment and prevention of cancer and pharmaceutical compositions containing the same | 株式会社大熊制药 | 2024-10-29 | — | — | CN | disclosed |
| US-20240165121-A1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2024-05-23 | — | — | US | disclosed |
| EP-4010080-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-11642348-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642348-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642348-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2023067354-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| US-20220298134-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| US-20140142083-A1 | Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-05-22 | — | — | US | disclosed |
| WO-2014062733-A2 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014062733-A2 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2014-04-24 | — | — | WO | disclosed |
| EP-2697198-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012142513-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2012-10-18 | — | — | WO | disclosed |
| EP-2420492-A1 | METHOD FOR PRODUCING 2-HALOGENO-6-SUBSTITUTED-4-TRIFLUOROMETHYLPYRIDINE | Ishihara Sangyo Kaisha, Ltd. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120035372-A1 | METHOD FOR PRODUCING 2-HALOGENO-6-SUBSTITUTED-4-TRIFLUOROMETHYLPYRIDINE | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2012-02-09 | — | — | US | disclosed |
| EP-0104876-B1 | HERBICIDAL CYCLOHEXANE-1,3-DIONE DERIVATIVES | ICI AUSTRALIA LIMITED (AU) | 1991-12-27 | — | — | EP | disclosed |
| US-4631081-A | Herbicidal cyclohexane-1,3-dione derivatives | ICI AUSTRALIA LIMITED (AU) | 1986-12-23 | — | — | US | disclosed |
| EP-0104876-A2 | Herbicidal cyclohexane-1,3-dione derivatives | ICI AUSTRALIA LIMITED (AU) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | KDM4E 1609/4885ALDH1A1 97/4885GLA 500/4885 |
| US-20220298134-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | KDM4E 1609/4885ALDH1A1 97/4885GLA 500/4885 |
| US-20240165121-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | KDM4E 711/4885ALDH1A1 358/4885GLA 2461/4885 |
| US-20140142083-A1 | Substituted Benzene Compounds | CYP1B1, TP53, VHL | KDM4E 711/4885ALDH1A1 358/4885GLA 2461/4885 |
| US-20120035372-A1 | METHOD FOR PRODUCING 2-HALOGENO-6-SUBSTITUTED-4-TRIFLUOROMETHYLPYRIDINE | RDX, CYP4X1, BRIX1 | KDM4E 447/4885ALDH1A1 1871/4885GLA 2441/4885 |
| US-11642348-B2 | Substituted benzene compounds | CYP1B1, TP53, VHL | KDM4E 711/4885ALDH1A1 358/4885GLA 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.